MedTrace Logo

A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2

NCT04721535 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2022-12-07

No results posted yet for this study

Summary

To evaluate the prevention of SARS-COV-2 infection after administration of DWJ1248 in person who contact from COVID-19 confirmed patient compared to the placebo.

Conditions

Interventions

DRUG

DWJ1248

Orally, 1 tablet of DWJ1248 TID, up to 14 days

DRUG

Placebo

Orally, 1 tablet of placebo TID, up to 14 days

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-07
Primary Completion
2021-09-23
Completion
2021-10-06

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04721535 on ClinicalTrials.gov